Results 51 to 60 of about 19,821,917 (190)

Prevention of thromboembolic complications in patients with atrial fibrillation and obesity

Annales Academiae Medicae Silesiensis, 2023
Atrial fibrillation (AF) is an arrhythmia that occurs in 1–2% of the population. Chronic oral anticoagulation is recommended in the group of patients with AF to prevent thromboembolic complications. Obesity is a factor contributing to the development and
Izabela Kolasa, Beata Średniawa
doaj   +1 more source

Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants [PDF]

, 2017
Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major adverse events and medication adherence is central to achieve good ...
Lane, Deirdre A, Lip, Gregory, Lane, Deirdre, Stefania, Basili, Raparelli, Valeria, Lane, Deirdre A., Lip, Gregory Y. H., Lip, Gregory Y H, Basili, Stefania, Proietti, Marco, Cangemi, Roberto   +10 more
core   +1 more source

Characteristics in Non–Vitamin K Antagonist Oral Anticoagulant–Related Intracerebral Hemorrhage [PDF]

Stroke, 2019
Background and Purpose— Given inconclusive studies, it is debated whether clinical and imaging characteristics, as well as functional outcome, differ among patients with intracerebral hemorrhage (ICH) related to vitamin K antagonists (VKA) versus non–vitamin K antagonist (NOAC)-related ICH.
Gerner, Stefan T., Kuramatsu, Joji B., Sembill, Jochen A., Sprügel, Maximilian I., Hagen, Manuel, Knappe, Ruben U., Endres, Matthias, Haeusler, Karl Georg, Sobesky, Jan, Schurig, Johannes, Zweynert, Sarah, Bauer, Miriam, Vajkoczy, Peter, Ringleb, Peter A., Purrucker, Jan C., Rizos, Timolaos, Volkmann, Jens, Müllges, Wolfgang, Kraft, Peter, Schubert, Anna-Lena, Erbguth, Frank, Nueckel, Martin, Schellinger, Peter D., Glahn, Jörg, Knappe, Ulrich J., Fink, Gereon R., Dohmen, Christian, Stetefeld, Henning, Fisse, Anna Lena, Minnerup, Jens, Hagemann, Georg, Rakers, Florian, Reichmann, Heinz, Schneider, Hauke, Rahmig, Jan, Ludolph, Albert Christian, Stösser, Sebastian, Neugebauer, Hermann, Röther, Joachim, Michels, Peter, Schwarz, Michael, Reimann, Gernot, Bäzner, Hansjörg, Schwert, Henning, Claßen, Joseph, Michalski, Dominik, Grau, Armin, Palm, Frederick, Urbanek, Christian, Wöhrle, Johannes C., Alshammari, Fahid, Horn, Markus, Bahner, Dirk, Witte, Otto W., Günther, Albrecht, Hamann, Gerhard F., Engelhorn, Tobias, Lücking, Hannes, Dörfler, Arnd, Schwab, Stefan, Huttner, Hagen B.   +60 more
openaire   +3 more sources

Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies, Elin Haf Davies, Dyfrig A. Hughes   +2 more
wiley   +1 more source

Baseline characteristics of patients treated with warfarin vs. non-vitamin K antagonist oral anticoagulants (NOACs).

, 2019
Baseline characteristics of patients treated with warfarin vs. non-vitamin K antagonist oral anticoagulants (NOACs).
Robert Klempfner (326258), Maya Koren-Michowitz (267119), Nir Shlomo (686408), Ilan Goldenberg (326261), Yoav Michowitz (7832888)   +4 more
core   +1 more source

Preparation and Characterization of Isradipine as Surfactant-Free Dry Emulsion

مجلة كلية الطب
Background: Oral anticoagulation medication, warfarin, and non-vitamin K antagonist oral anticoagulants (NOAC) may require long-term use which may affect patients’ satisfaction with their treatment and their quality of life (QOL).
Zahraa M. Al-Sharify, Fatima J. Jawad
doaj   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation

TH Open, 2018
Background Vitamin K antagonists (VKAs) are associated with coronary artery calcification in low-risk populations, but their effect on calcification of large arteries remains uncertain.
Frederique E. C. M. Peeters, Elton A. M. P. Dudink, Dorien M. Kimenai, Bob Weijs, Sibel Altintas, Luuk I. B. Heckman, Casper Mihl, Leon J. Schurgers, Joachim E. Wildberger, Steven J. R. Meex, Bas L. J. H. Kietselaer, Harry J. G. M. Crijns   +11 more
doaj   +1 more source

Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions [PDF]

Netherlands Heart Journal, 2019
Non-vitamin K antagonist oral anticoagulants (NOACs) are prescribed to patients with atrial fibrillation (AF) to reduce the risk of stroke. Prescribing the correct dose warrants careful consideration of the prevailing dose criteria that differ per NOAC. Electronic systems are useful to intercept prescriptions that are incorrect based on simple 'primary'
M. S. Jacobs, M. van Hulst, Z. Campmans, R. G. Tieleman   +3 more
openaire   +2 more sources

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

BMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang, Yu‐zhu Wang, Yi‐fei Wang, Que Bai, Jia‐xin Hao, Zhi‐ting Li, Xiao‐qing Cao, Yu Wei, Yue Feng, Ji‐hua Chen, Franklin R. Tay, Rui‐bing Wang, Jun‐ting Gu, Li‐na Niu   +13 more
wiley   +1 more source